SYROS PHARMACEUTICALS, INC.

(SYRS)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
0.9100 USD   -5.47%
07/01Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 2500 Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 2000 Dynamic Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
0.9573(c) 0.9109(c) 0.9592(c) 0.9627(c) 0.91(c) Last
500 802 387 303 334 134 201 194 221 376 Volume
+7.39% -4.85% +5.30% +0.36% -5.47% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 19,8 M - -
Net income 2022 -108 M - -
Net cash position 2022 30,2 M - -
P/E ratio 2022 -0,56x
Yield 2022 -
Sales 2023 16,7 M - -
Net income 2023 -135 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,46x
Yield 2023 -
Capitalization 57,2 M 57,2 M -
EV / Sales 2022 1,36x
Capi. / Sales 2023 3,43x
Nbr of Employees 124
Free-Float 95,0%
More Financials
Company
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefending the power of small molecules to control the expression of genes. The Company is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical-stage pipeline of gene control medicine. The Company's lead product candidates... 
More about the company
Ratings of Syros Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SYROS PHARMACEUTICALS, INC.
07/01Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 2500 Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 2000 Dynamic Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 2000 Value Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell Small Cap Comp Value Ind..
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 2500 Value Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 3000E Value Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 2000 Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 2000 Growth Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell Small Cap Comp Growth In..
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 3000 Growth Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 3000E Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 3000E Growth Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 3000 Value Index
CI
06/24SYROS PHARMACEUTICALS, INC.(NASDAQGS : SYRS) dropped from Russell 3000 Index
CI
More news
News in other languages on SYROS PHARMACEUTICALS, INC.
05/16Syros Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 ..
04/08Syros Pharmaceuticals, Inc. présente de nouvelles données précliniques sur son programm..
03/15Earnings Flash (SYRS) SYROS PHARMACEUTICALS affiche un chiffre d'affaires de 7,8 millio..
03/15Syros Pharmaceuticals, Inc. annonce ses résultats pour le quatrième trimestre et l'anné..
03/15Syros Pharmaceuticals, Inc. Le vérificateur remet en question la continuité de l'exploi..
More news
Analyst Recommendations on SYROS PHARMACEUTICALS, INC.
More recommendations
Chart SYROS PHARMACEUTICALS, INC.
Duration : Period :
Syros Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYROS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,91 $
Average target price 13,00 $
Spread / Average Target 1 329%
EPS Revisions
Managers and Directors
Nancy A. Simonian President, Chief Executive Officer & Director
Jason Haas Chief Financial Officer
Peter Wirth Chairman
Eric R. Olson Chief Scientific Officer
David A. Roth Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SYROS PHARMACEUTICALS, INC.-72.09%57
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.83%40 011
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.60%19 031